The project in the news
​Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses
​
​
​
Clinically-relevant correction of Recessive Dystrophic Epidermolysis Bullosa by dual sgRNA CRISPR/Cas9-mediated gene editing
​
Designación de medicamento huérfano: Autologous skin equivalent graft composed of keratinocytes and fibroblasts genetically corrected by CRISPR/Cas9-mediated excision of mutation-carrying COL7A1 exon 80.
Indicación: Tratamiento de la epidermólisis bullosa
PROMOTOR: CIBERER
ENTIDADES PARTICIPANTES: CIEMAT (25%), CIBERER (30%), UC3M (33%), CCST (2%), FJD (10%)
Inventores: F Larcher, R Murillas, A Mencia, J Bonafont, MJ Escámez, A Meana, SG Llames, S Modamio, MC de Arriba, L Martínez, M García, M del Río,
Aceptación EMA: 28/02/2020.
Referencia: EMA/OD/0000013899
​
​
News for EB Patients and Professionals
DEBRA-Spain
The DEBRA- Butterfly Skin Association is a national reference in Epidermolysis bullosa that has the declaration of Public Utility issued by the Ministry of the Interior.
The International Clinical Network of EB Centers and Experts promotes the exchange of EB knowledge and experience to ensure professional treatment for patients and a simplification of cross-border medical care as well as to create a basis for future clinical studies for the treatment of EB .
The portal on rare diseases and orphan drugs that gathers and improves knowledge to improve the diagnosis, care and treatment of people who suffer from them.